Y-mAbs Therapeutics Financial Health

Short Term Liabilities: YMAB's short term assets ($133.2M) exceed its short term liabilities ($32.0M).

Long Term Liabilities: YMAB's short term assets ($133.2M) exceed its long term liabilities ($4.0M).

Debt Level: YMAB is debt free.

Reducing Debt: YMAB has not had any debt for past 5 years.

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: YMAB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: YMAB has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 27.7% each year.

• Healthy companies in the Pharmaceuticals & Biotech industry.